» Articles » PMID: 38316684

Shared Medical Decision in Prostate Cancer Screening in Primary Care: a Systematic Literature Review of Current Evidence

Overview
Publisher Springer
Specialty Nephrology
Date 2024 Feb 5
PMID 38316684
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Prostate cancer screening has not significantly reduced mortality. International guidelines strongly endorse shared decision-making to navigate risks, emphasizing its crucial role prior to prescribing a prostate-specific antigen test. This study aims to provide insight into the current role of shared decision-making in primary care for prostate cancer screening and suggest ways to improve the process.

Methods: PubMed, Cochrane, and Lissa databases were searched for following terms: 'prostate-specific antigen' or 'prostate cancer screening' combined with 'shared decision making', 'informed decision making' or 'decision support' and 'primary care'. All studies were screened by two independent reviewers. This systematic review followed the PRISMA guidelines.

Results: Of 85 articles screened, 34 were included. Key findings included heterogenous and poor quality implementation of shared decision-making in practice, patients with limited knowledge of shared decision-making, clinicians infrequently discussing patients' views, decision aids that could be better integrated into practice, and finally, changes in care systems to support the expansion of shared decision-making in prostate cancer screening.

Conclusion: Decision aids are essential tools in the informed decision-making process. Integrating these elements into practice would require training for doctors and adjustments to the healthcare system.

References
1.
Martin R, Donovan J, Turner E, Metcalfe C, Young G, Walsh E . Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. JAMA. 2018; 319(9):883-895. PMC: 5885905. DOI: 10.1001/jama.2018.0154. View

2.
Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-9. PMC: 2944770. DOI: 10.1056/NEJMoa0810696. View

3.
Charvin M, Moutel G, Launoy G, Berchi C . . Sante Publique. 2022; 34(1):107-118. DOI: 10.3917/spub.221.0107. View

4.
Taylor K, Luta G, Hoffman R, Davis K, Lobo T, Zhou Y . Quality of life among men with low-risk prostate cancer during the first year following diagnosis: the PREPARE prospective cohort study. Transl Behav Med. 2018; 8(2):156-165. PMC: 6256951. DOI: 10.1093/tbm/ibx005. View

5.
Srivastava S, Koay E, Borowsky A, De Marzo A, Ghosh S, Wagner P . Cancer overdiagnosis: a biological challenge and clinical dilemma. Nat Rev Cancer. 2019; 19(6):349-358. PMC: 8819710. DOI: 10.1038/s41568-019-0142-8. View